ArticlePloS one2026
Exercise-based cardiac rehabilitation and atherosclerotic plaque regression in ASCVD: Is exercise really a game-changer? A scoping review of controlled trials.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Exercise-based cardiac rehabilitation (CR) has emerged as a promising strategy for promoting atherosclerotic plaque regression in patients with atherosclerotic cardiovascular disease (ASCVD). Although lipid-lowering drugs are firmly established for plaque regression, the impact of exercise-based CR on plaque regression remains underexplored, prompting synthesis of existing evidence. This review aims to characterize studies on exercise-based CR in ASCVD, summarize CR modalities, identify confounding factors, and evaluate evidence of plaque regression from imaging and clinical outcomes. A thorough literature search was conducted in May-June 2025 across PubMed, ScienceDirect, and EBSCO. Included studies were controlled trials on CR for ASCVD adults assessing plaque changes via imaging. Data extraction followed PRISMA-ScR guidelines focusing on study design, populations, interventions, and outcomes. Five trials encompassing 217 participants demonstrated that diverse CR programmes-high-intensity interval training, aerobic exercise and resistance training-combined with standard medical therapy significantly reduced plaque volume parameters, as measured by IVUS and carotid ultrasound. CR further improved key mechanistic markers, including inflammatory cytokines and endothelial function, underpinning plaque stabilization and regression. Exercise-based CR robustly promotes plaque regression and mitigates cardiovascular risk in ASCVD, complementing pharmacological approaches. These findings affirm CR's indispensable role in secondary prevention, though confounding from concurrent lipid-lowering therapies warrants consideration in future randomized trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.